Category: Parkinson's Disease: Non-Motor Symptoms
Objective: Due to the high prevalence of mild cognitive impairment (MCI) in Parkinson disease (PD), routine cognitive screening is important for the optimal management of patients with PD. The aim of this study was to validate the reliability of the Chinese version of Addenbrooke’s Cognitive Examination III (ACE-III) for detecting MCI with PD in China. Furthermore, the present study compares the diagnostic accuracy of ACE-III with that of Montreal Cognitive Assessment (MoCA).
Background: The ACE-III was reported as a screening tool to detect cognition. The Chinese version of ACE-III has been proved to be a reliable assessment tool for MCI. To the best of our knowledge, there has been no report about the utility of the Chinese version of ACE-III in the diagnosis of MCI in PD.
Method: A representative sample of 80 MCI patients with PD from Geriatric Hospital of Nanjing Medical University was administered. Our MCI criteria were (1) MMSE score < 24；(2) self-report of cognitive decline; and (3) not impairment of activities of daily living (ADL). The demographic and clinical profiles of all participants were collected. All patients were evaluated by the Chinese version of ACE-III and MoCA.
Results: There was a significantly positive correlation between ACE-III total score and MMSE score. Meanwhile, there was also a significantly positive correlation between ACE-III total score and MoCA score. For ACE-III total score, a cut-off point of 85 yielded a sensitivity of 88.3% and a specificity of 86.7%. The AUC for ACE-III total score was 0.898. For MoCA, a cut-off point of 24 yielded a sensitivity of 86.5% and a specificity of 82.7%. The AUC for MoCA was 0.886. There were no significant differences in diagnostic accuracy between ACE-III and MoCA.
Conclusion: The present findings support that both ACE-III and MoCA are useful for detecting MCI patients with PD.
To cite this abstract in AMA style:
H. Zheng, D. Huang, C. Xu, Y. sun. Comparative diagnostic accuracy of ACE-III and MoCA for detecting mild cognitive impairment patients with Parkinson’s disease [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/comparative-diagnostic-accuracy-of-ace-iii-and-moca-for-detecting-mild-cognitive-impairment-patients-with-parkinsons-disease/. Accessed May 19, 2025.« Back to MDS Virtual Congress 2020
MDS Abstracts - https://www.mdsabstracts.org/abstract/comparative-diagnostic-accuracy-of-ace-iii-and-moca-for-detecting-mild-cognitive-impairment-patients-with-parkinsons-disease/